checkAd

    INVESTOR ALERT  353  0 Kommentare Levi & Korsinsky, LLP Notifies Shareholders of Lipocine Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 30, 2016 -- LPCN

    NEW YORK, NY--(Marketwired - July 12, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:

    To: All persons or entities who purchased or otherwise acquired securities of Lipocine Inc. ("Lipocine" or "the Company") (NASDAQ: LPCN) between June 30, 2015 and June 28, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Apple Inc.!
    Long
    172,17€
    Basispreis
    1,19
    Ask
    × 14,75
    Hebel
    Short
    196,80€
    Basispreis
    1,15
    Ask
    × 14,75
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    http://www.zlk.com/pslra/lipocine-inc

    or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

    The complaint alleges that throughout the Class Period, defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Lipocine's filing of its New Drug Application for LPCN 1021, Lipocine's lead product candidate, contained deficiencies; and (2) as a result, defendant's statements about Lipocine's business and operations were false and misleading and/or lacked a reasonable basis.

    On June 29, 2016, Lipocine announced that the U.S. Food and Drug Administration had issued a Complete Response Letter regarding the Company's New Drug Application for LPCN 1021. According to the Complete Response Letter, the FDA has identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form.

    If you suffered a loss in Lipocine you have until August 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

    Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

    Lesen Sie auch

    CONTACT:
    Levi & Korsinsky, LLP
    Joseph E. Levi, Esq.
    30 Broad Street - 24th Floor
    New York, NY 10004
    Tel: (212) 363-7500
    Toll Free: (877) 363-5972
    Fax: (212) 363-7171
    www.zlk.com





    Verfasst von Marketwired
    INVESTOR ALERT Levi & Korsinsky, LLP Notifies Shareholders of Lipocine Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 30, 2016 -- LPCN NEW YORK, NY--(Marketwired - July 12, 2016) - The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Lipocine Inc. ("Lipocine" or "the Company") (NASDAQ: LPCN) …

    Schreibe Deinen Kommentar

    Disclaimer